These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 2901184)

  • 1. The synthetic peptide GRF (1-29)-NH2 with growth hormone releasing activity penetrates human epidermis in nitro.
    Lodén M; Faijerson Y
    Acta Pharm Suec; 1988; 25(1):27-30. PubMed ID: 2901184
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent long-acting alkylated analogs of growth hormone-releasing factor.
    Murphy WA; Coy DH
    Pept Res; 1988; 1(1):36-41. PubMed ID: 2908793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS; Lee KC
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary.
    Gaudreau P; Boulanger L; Abribat T
    J Med Chem; 1992 May; 35(10):1864-9. PubMed ID: 1534126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide.
    Rafferty B; Coy DH; Poole S
    Peptides; 1988; 9(1):207-9. PubMed ID: 2896343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GH response to GRF (1-29) NH2 in female rats treated neonatally with estradiol benzoate or testosterone propionate.
    Aguilar E; López F
    J Steroid Biochem; 1988 Jun; 29(6):727-9. PubMed ID: 2898557
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs.
    D'Antonio M; Louveau I; Esposito P; Bertolino M; Canali S
    Growth Horm IGF Res; 2004 Jun; 14(3):226-34. PubMed ID: 15125884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Response of growth hormone to GRF(1-29)NH2 in 12 cases of active acromegaly].
    Santos Español C; Acosta Delgado D; García-Luna P; Navarro González E; Gavilán Villarejo I; Fernández López I; Leal del Cerro A; García de Pesquera F; Astorga Jiménez R
    Rev Clin Esp; 1987 Mar; 180(5):242-6. PubMed ID: 2885902
    [No Abstract]   [Full Text] [Related]  

  • 9. Growth hormone response to GRF 1-44 in children following cranial irradiation for central nervous system tumors.
    Oberfield SE; Kirkland JL; Frantz A; Allen JC; Levine LS
    Am J Pediatr Hematol Oncol; 1987; 9(3):233-8. PubMed ID: 3118729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of pigs as an animal model to evaluate the efficacy, potency and specificity of two growth hormone releasing factor analogues.
    Dubreuil P; Brazeau P; Moreau S; Farmer C; Coy D; Abribat T
    Growth Horm IGF Res; 2001 Jun; 11(3):173-86. PubMed ID: 11735232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of growth hormone-releasing factor on growth hormone release in children with radiation-induced growth hormone deficiency.
    Lustig RH; Schriock EA; Kaplan SL; Grumbach MM
    Pediatrics; 1985 Aug; 76(2):274-9. PubMed ID: 3927254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs.
    Felix AM; Lu YA; Campbell RM
    Int J Pept Protein Res; 1995; 46(3-4):253-64. PubMed ID: 8537179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue and plasma distribution of exogenous growth hormone-releasing factor analogue (GRF1-29NH2) after intravenous, subcutaneous and intraperitoneal injection in the rat.
    Fernandez-Gonzalez MA; Barrios V; Sancho JI; Arilla E; Carmena MJ; Tresguerres JA; Prieto JC
    Gen Pharmacol; 1987; 18(5):551-4. PubMed ID: 2888706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Somatocrinin and children in 1984. Application to the etiological diagnosis of somatotropin deficiencies].
    Chatelain P; Bertrand J; David M; Sassolas G; Catbeh N; Morel Y; Ruitton A; Ferry S; Gilly R; Philip T
    Arch Fr Pediatr; 1985 Mar; 42(3):205-9. PubMed ID: 3923994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of iontophoresis on in vitro skin permeation of an analogue of growth hormone releasing factor in the hairless guinea pig model.
    Kumar S; Char H; Patel S; Piemontese D; Iqbal K; Malick AW; Neugroschel E; Behl CR
    J Pharm Sci; 1992 Jul; 81(7):635-9. PubMed ID: 1403695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on peptides. CXX. Synthesis of growth hormone releasing factor (GRF-37-NH2) and N alpha-biotinyl-GRF-44-NH2.
    Fujii N; Shimokura M; Yajima H; Shono F; Tsuda M; Yoshitake A
    Chem Pharm Bull (Tokyo); 1984 Mar; 32(3):1200-8. PubMed ID: 6430578
    [No Abstract]   [Full Text] [Related]  

  • 17. Applications of BOP reagent in solid phase synthesis. Advantages of BOP reagent for difficult couplings exemplified by a synthesis of [Ala 15]-GRF(1-29)-NH2.
    Fournier A; Wang CT; Felix AM
    Int J Pept Protein Res; 1988 Jan; 31(1):86-97. PubMed ID: 2896637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration.
    Rafferty B; Poole S; Clarke R; Schulster D
    J Endocrinol; 1985 Dec; 107(3):R5-8. PubMed ID: 2866222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs recently released in Belgium. Recombinant methionyl human growth hormone, synthetic growth hormone-releasing factor, somatostatin.
    Harvengt C
    Acta Clin Belg; 1987; 42(1):62-5. PubMed ID: 2884791
    [No Abstract]   [Full Text] [Related]  

  • 20. [Talc tablet method in HGH radioimmunoassay].
    Ogawa N; Takahara J; Ofuji M
    Horumon To Rinsho; 1972 May; 20(5):387-91. PubMed ID: 5066453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.